1-9 of 9
Eric Hedrick
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Clinical Practice Comparison of Overall Survival, Time-to-Next-Treatment, and Time-to-Treatment-Discontinuation Among CLL/SLL Patients Receiving First-Line Ibrutinib with and without a Del(17p) Mutation

Anthony Mato, MD, Boxiong Tang, MD PhD, Soraya Azmi, MBBS,MPH, Keri Yang, PhD MPH, MS, Jennifer C Stern, PhD, Eric Hedrick, MD, Jane Huang, MD, Jeff P Sharman, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–3.
https://doi.org/10.1182/blood-2020-134119
Published: 2020
Journal Articles

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Clinical Trials & Observations
Eytan M. Stein, Guillermo Garcia-Manero, David A. Rizzieri, Raoul Tibes, Jesus G. Berdeja, Michael R. Savona, Mojca Jongen-Lavrenic, Jessica K. Altman, Blythe Thomson, Stephen J. Blakemore, Scott R. Daigle, Nigel J. Waters, A. Benjamin Suttle, Alicia Clawson, Roy Pollock, Andrei Krivtsov, Scott A. Armstrong, Jorge DiMartino, Eric Hedrick, Bob Löwenberg, Martin S. Tallman
Journal: Blood
Blood (2018) 131 (24): 2661–2669.
https://doi.org/10.1182/blood-2017-12-818948
Published: 2018
Includes: Supplemental data
Journal Articles

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

Constantine S. Tam, MD, Hang Quach, MBBS, MD, Andrew Nicol, Xavier Badoux, Hannah Rose, H. Miles Prince, MD FRACP, FRCPA, Michael F. Leahy, FRACP,FRCPath,FRCP, Richard Eek, MBCHB, Nicholas Wickham, FRCPA,FRACP,FRCPath, Sushrut S. Patil, FRACP, FRCPA, Jane Huang, MD, Xiaoping Zhang, MD PhD, Lai Wang, PhD, Eric Hedrick, MD, William Novotny, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1745.
https://doi.org/10.1182/blood.V130.Suppl_1.1745.1745
Published: 2017
Journal Articles

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Constantine S. Tam, MBBS, Judith Trotman, MBChB, Stephen Opat, MD, Paula Marlton, MBBS, Gavin Cull, MBBS DM FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Matthew Ku, MBBS, David Ritchie, MD PhD, Emma Verner, FRACP, FRCPA, MBBS, Sumita Ratnasingam, MBBS, Mary Ann Anderson, MBBS, Peter Wood, MD FRACP, FRCPA, MBBS, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts
Journal: Blood
Blood (2016) 128 (22): 1216.
https://doi.org/10.1182/blood.V128.22.1216.1216
Published: 2016
Journal Articles

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Constantine S. Tam, MBBS, Stephen Opat, MD, Gavin Cull, MBBS DM FRACP FRCPA, Judith Trotman, MBChB, David Gottlieb, MBBS MD FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Paula Marlton, MBBS, Mary Ann Anderson, MBBS, Matthew Ku, MBBS, David Ritchie, MD PhD, Sumita Ratnasingam, MBBS, Bradley Augustson, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts
Journal: Blood
Blood (2016) 128 (22): 642.
https://doi.org/10.1182/blood.V128.22.642.642
Published: 2016
Journal Articles

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Constantine Tam, MBBS, MD, Andrew P Grigg, MBBS MD, Stephen Opat, MBBS, Matthew Ku, MBBS, Michael Gilbertson, MBBS, Mary Ann Anderson, MBBS, John F. Seymour, MBBS, PhD, David S. Ritchie, MDPhD, Carmen Dicorleto, Belinda Dimovski, Eric Hedrick, Jianxin Yang, Lai Wang, PhD, Lusong Luo, Ling Xue, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2015) 126 (23): 832.
https://doi.org/10.1182/blood.V126.23.832.832
Published: 2015
Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study

Susan O'Brien, MD, Jan A. Burger, MD, PhD, Kristie A. Blum, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Jeff Sharman, MD, Ian W. Flinn, MD, PhD, Barbara Grant, MD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Tasheda Navarro, Eric Holmgren, PhD, Eric Hedrick, MD, John C. Byrd, MD
Journal: Blood
Blood (2011) 118 (21): 983.
https://doi.org/10.1182/blood.V118.21.983.983
Published: 2011
Journal Articles

The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial

Luhua Wang, MD, Peter Martin, MD, Kristie A. Blum, MD, Brad S. Kahl, MD, Lauren S. Maeda, MD, Ranjana Advani, MD, Michael E. Williams, MD, Simon Rule, MD, Sara Rodriguez, Ching-Fai Pang, PhD, Eric Hedrick, MD, Andre Goy, MD
Journal: Blood
Blood (2011) 118 (21): 442.
https://doi.org/10.1182/blood.V118.21.442.442
Published: 2011
Journal Articles

The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL

Louis M. Staudt, MD, PhD, Kieron Dunleavy, MD, Joseph J. Buggy, PhD, Eric Hedrick, MD, Nicole Lucas, RN, Stefania Pittaluga, MD, Sameer Jhavar, MD, Roland Schmitz, PhD, Mickey Williams, Ph.D., Jason Lih, PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2716.
https://doi.org/10.1182/blood.V118.21.2716.2716
Published: 2011